A recent study in over 117,000 patients with stage I to III rectal cancer highlights the importance of timely treatment. Study results indicate that starting treatment within 60 days of initial evaluation significantly improves overall survival. Patients who received timely treatment lived about 25 months longer on average compared to those with delayed treatment.
Key findings:
- Timely treatment benefits:
- Improved overall survival
- Better outcomes for patients with stage II and III cancer
- Factors associated with timely treatment:
- Higher income
- Receiving chemotherapy or chemoradiation as initial treatment
- Disparities in timely treatment:
- Black and Hispanic patients were more likely to experience treatment delays
- Patients with multiple health conditions also faced delays
The researchers conclude that addressing socioeconomic disparities and ensuring timely treatment for all patients is crucial for improving rectal cancer survival rates. As treatment becomes more complex, starting promptly remains essential for the best outcomes.
This study supports the efforts of the National Accreditation Program for Rectal Cancer (NAPRC), which aims to standardize and improve rectal cancer care across the United States.
More Reading
Treatment & Management of Rectal Cancer
Ask the Experts About Circulating Tumor DNA in the Management of Cancer
Join the conversation on CancerConnect!
Reference
Sun J, Fredette JD, Hasler JS, et al. Effect of Rectal Cancer Treatment Timing Standardization on Patient Outcomes. Am J Clin Oncol. 2025 Feb 10.
